T. Rowe Price Associates’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $61.6M | Sell |
|
|||||
|
2025
Q2 | $77.7M | Buy |
|
|||||
|
2025
Q1 | $61.9M | Sell |
|
|||||
|
2024
Q4 | $89.9M | Buy |
|
|||||
|
2024
Q3 | $97.9M | Sell |
|
|||||
|
2024
Q2 | $117M | Buy |
|
|||||
|
2024
Q1 | $130M | Buy |
|
|||||
|
2023
Q4 | $16.7M | Sell |
|
|||||
|
2023
Q3 | $12.9M | Sell |
|
|||||
|
2023
Q2 | $16.2M | Sell |
|
|||||
|
2023
Q1 | $25.7M | Sell |
|
|||||
|
2022
Q4 | $37.1M | Buy |
|
|||||
|
2022
Q3 | $21M | Buy |
|
|||||
|
2022
Q2 | $14.4M | Sell |
|
|||||
|
2022
Q1 | $35.9M | Buy |
|
|||||
|
2021
Q4 | $35.4M | Buy |
|
|||||
|
2021
Q3 | $47.4M | Buy |
|
|||||
|
2021
Q2 | $13M | Buy |
|
|||||
|
2021
Q1 | $6.84M | Buy |
|
|||||
|
2020
Q4 | $5.13M | Buy |
|
|||||
|
2019
Q1 | – | Sell |
|
|||||
|
2018
Q4 | $21K | Hold |
|
|||||
|
2018
Q3 | $48K | Hold |
|
|||||
|
2018
Q2 | $53K | Sell |
|
|||||
|
2018
Q1 | $247K | Buy |
|
|||||
|
2017
Q4 | $246K | Sell |
|
|||||
|
2017
Q3 | $419K | Buy |
|
|||||
|
2017
Q2 | $312K | Buy |
|
|||||
|
2017
Q1 | $432K | Buy |
|
|||||
|
2016
Q4 | $405K | Hold |
|
|||||
|
2016
Q3 | $462K | Buy |
|
|||||
|
2016
Q2 | $484K | Buy |
|
|||||
|
2016
Q1 | $281K | Buy |
|
|||||
|
2015
Q4 | $771K | Sell |
|
|||||
|
2015
Q3 | $535K | Buy |
|
|||||
|
2015
Q2 | $1.24M | Buy |
|
|||||
|
2015
Q1 | $1.27M | Hold |
|
|||||
|
2014
Q4 | $831K | Sell |
|
|||||
|
2014
Q3 | $673K | Buy |
|
|||||
|
2014
Q2 | $618K | Buy |
|
|||||
|
2014
Q1 | $589K | Hold |
|
|||||
|
2013
Q4 | $807K | Sell |
|
|||||
|
2013
Q3 | $1.42M | Sell |
|
|||||
|
2013
Q2 | $675K | Buy |
|